Company · ZYME
Zymeworks Inc.
Nasdaq's symbol directory lists ZYME on Nasdaq as “Zymeworks Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 3 occasions ($1.8M); 3 planned-sale notices; 4 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 31
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Moore Paul Andrew, Chief Scientific Officer sold $1.0M
- Platshon Scott, EVP, Chief Business Officer sold $382K
- Schayowitz Adam, EVP, Head of R&D sold $358K
Every trade (3)
- SELLPlatshon Scott, EVP, Chief Business Officer sold $382K
- SELLMoore Paul Andrew, Chief Scientific Officer sold $1.0M
- SELLSchayowitz Adam, EVP, Head of R&D sold $358K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Scott Platshon $395K
- Paul Andrew Moore $1.1M
- Adam Schayowitz $349K
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Regulation FD disclosure; Other events Nov 16, 2026
- Results of operations and financial condition; Regulation FD disclosure Nov 9, 2026
- Entry into a material definitive agreement; Regulation FD disclosure Oct 23, 2026
- Entry into a material definitive agreement; Completion of acquisition or disposition of assets; Creation of a direct financial obligation; Regulation FD disclosure Sep 23, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.